Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 13/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.77 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.77 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.77 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.77 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.77 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.77 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31018036 | 1.00 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877854 | 1.00 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877853 | 1.00 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL19464266 | 0.99 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL10380334 | 0.99 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL7447363 | 0.99 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL27075590 | 0.99 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL31018017 | 0.99 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL399278 | 0.99 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL30734435 | 0.99 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2806276-A1 | Method for post mortem diagnosis of Alzheimer's Disease (AD) | Red Bull GmbH (AT) | 2014-11-26 | — | — | EP | claimed |
| EP-1917277-A4 | KILLING HUMAN LYMPHOMA AND LEUKEMIA CANCER CELLS AND TCR-ACTIVATED NORMAL HUMAN CELLS BY DOPAMINE D1R AGONISTS | LEVITE MIA (IL) | 2009-08-05 | — | — | EP | claimed |
| US-20080311657-A1 | Killing Human Lymphoma and Leukemia Cancer Cells and Tcr-Activated Normal Human Cells By Dopamine D1r Agonists | LEVITE MIA | 2008-12-18 | — | — | US | claimed |
| EP-1917277-A2 | KILLING HUMAN LYMPHOMA AND LEUKEMIA CANCER CELLS AND TCR-ACTIVATED NORMAL HUMAN CELLS BY DOPAMINE D1R AGONISTS | Mineuet Therapeutics Ltd. (IL) | 2008-05-07 | — | — | EP | claimed |
| WO-2007019266-A2 | KILLING HUMAN LYMPHOMA AND LEUKEMIA CANCER CELLS AND TCR-ACTIVATED NORMAL HUMAN CELLS BY DOPAMINE D1R AGONISTS | MINEUET THERAPEUTICS LTD. (IL) | 2007-02-15 | — | — | WO | claimed |
| EP-2806276-A1 | Method for post mortem diagnosis of Alzheimer's Disease (AD) | Red Bull GmbH (AT) | 2014-11-26 | — | — | EP | disclosed |
| US-8859001-B2 | Fenoldopam formulations and pro-drug derivatives | LEVITE MIA (IL) | 2014-10-14 | — | — | US | disclosed |
| US-20110104287-A1 | FENOLDOPAM FORMULATIONS AND PRO-DRUG DERIVATIVES | LEVITE MIA | 2011-05-05 | — | — | US | disclosed |
| WO-2009052491-A2 | FENOLDOPAM FORMULATIONS AND PRODRUG DERIVATIVES | GERAGHTY, ERIN (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20080311657-A1 | Killing Human Lymphoma and Leukemia Cancer Cells and Tcr-Activated Normal Human Cells By Dopamine D1r Agonists | LEVITE MIA | 2008-12-18 | — | — | US | disclosed |
| US-20060039867-A1 | Method for treating sleep-related breathing disorders with setiptiline | CYPRESS BIOSCIENCE, INC. | 2006-02-23 | — | — | US | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5582801-A | HAVING PLURALITY OF REACTION TUBES WITH FILTERS ON LOWER ENDS, RESERVOIR WITH MEANS FOR RECEIVING FILTERS, HOLDER FOR SUPPORTING TUBES, MANIFOLD ENCLOSING UPPER ENDS, FASTENERS HOLDING TOGETHER HOLDER AND MANIFOLD, HOLDER AND RESERVOIR | WARNER-LAMBERT COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5567391-A | MULTICOMPARTMENT CHEMICAL REACTORS | WARNER-LAMBERT COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565173-A | USED FOR SOLID-PHASE SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5324483-A | Apparatus for multiple simultaneous synthesis | WARNER-LAMBERT COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |
| US-4963568-A | TREATMENT OF PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104287-A1 | FENOLDOPAM FORMULATIONS AND PRO-DRUG DERIVATIVES | NAPEPLD, PNLIP, NPSR1 | DRD1 87/4885ADRA2A 115/4885ADRA2B 72/4885 |
| US-20060039867-A1 | Method for treating sleep-related breathing disorders with setiptiline | SETD1A, SETD7, SETD2 | DRD1 583/4885ADRA2A 1622/4885ADRA2B 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.